甘李药业股份有限公司 关于重大合同的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，甘李药业股份有限公司（以下简称"公司"）与 Fundação Oswaldo Cruz -Bio-Manguinhos（以下简称"FZ"）以及 BIOMM S.A.（以下简称"BIOMM"） 就巴西生产开发伙伴关系计划项目（以下简称"PDP 项目"）签订了《技术转移 与供应协议》（以下简称"合同一"）。同时，公司与 BIOMM 签订了《供应框 架协议》（美元合同）（以下简称"合同二"），合同二总金额预计不低于人民 币 300,000.00 万元（含税），最终以实际订单金额为准。 上述合同系日常经营性合同，公司与交易对方均不存在关联关系，所涉及的 交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重大 资产重组。上述合同的签订在公司总经理审批权限范围内，已履行公司内部审批 程序。根据《上海证券交易所股票上市规则》和公司章程规定，上述合同无需提 交公司董事会和股东大会审议。 证券代码：603087 证券简称：甘李药业 公 ...

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM, which is expected to positively impact its operating performance in 2025 and beyond [1] Group 1: Agreements and Financial Implications - The technology transfer agreement involves the transfer of insulin technology and the supply of active pharmaceutical ingredients and injectable solutions [1] - The total amount of the supply framework agreement is expected to be no less than RMB 3 billion, with the final amount based on actual orders [1] - The signing of these contracts has been approved within the company's general manager's authority and has followed internal approval procedures [1] Group 2: Future Impact - The execution of these contracts is anticipated to enhance the company's overall profitability [1] - The agreements are expected to have a positive effect on the company's operating performance in 2025 and subsequent years [1]

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos and BIOMM, which is expected to positively impact its financial performance in 2025 and beyond [1] Group 1: Agreements - The technology transfer and supply agreement involves the transfer of insulin glargine technology and the supply of active pharmaceutical ingredients and injection solutions [1] - The total amount of the supply framework agreement is expected to be no less than RMB 3 billion, with the final amount determined by actual order values [1] - The signing of the contracts has been approved within the company's general manager's authority and has followed internal approval procedures [1] Group 2: Financial Impact - The execution of these contracts is anticipated to have a positive effect on the company's operating performance in 2025 and subsequent years [1] - The agreements are expected to enhance the overall profitability of the company [1]

Group 1 - A total of 22 companies were investigated by well-known institutions from September 15 to September 22 [1] - The automotive and electronics sectors received the most attention, followed by the biotechnology sector [1] - The company with the highest number of institutional investigations was Hanhigh Group, with 91 institutions participating, followed by World (86 institutions) and Ganli Pharmaceutical (84 institutions) [1] Group 2 - Notable investigations included companies such as Aobi Zhongguang (38 institutions), Welly Transmission (8 institutions), and Changhua Chemical (5 institutions) [2] - Other companies receiving significant attention were Chao Hong Ji (53 institutions), Sanxin Tourism (30 institutions), and Keshun Co. (30 institutions) [2] - Multiple institutions simultaneously investigated Hanhigh Group and Chao Hong Ji, indicating strong interest in these companies [2]

截至6月30日，甘李药业股东户数7.73万，较上期增加3.08%；人均流通股7165股，较上期减少2.99%。 2025年1月-6月，甘李药业实现营业收入20.67亿元，同比增长57.18%；归母净利润6.04亿元，同比增长 101.96%。 分红方面，甘李药业A股上市后累计派现16.12亿元。近三年，累计派现10.18亿元。 机构持仓方面，截止2025年6月30日，甘李药业十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股750.99万股，相比上期增加17.48万股。招商国证生物医药指数A（161726）位居第五大流 通股东，持股580.26万股，相比上期减少24.16万股。南方中证500ETF（510500）位居第六大流通股 东，持股536.87万股，相比上期增加69.27万股。创新药（159992）位居第八大流通股东，持股340.55万 股，为新进股东。南方阿尔法混合A（010357）位居第十大流通股东，持股264.69万股，为新进股东。 华安聚优精选混合（009714）退出十大流通股东之列。 责任编辑：小浪快报 9月23日，甘李药业盘中下跌2.01%，截至10:09，报72.12元/股，成 ...

Core Insights - In the past five trading days, a total of 281 companies were investigated by institutions, with notable interest in companies like Ganfeng Lithium, Hanhai Group, and Dingtong Technology [1][2] Group 1: Institutional Research Activity - 83.27% of the companies investigated had participation from securities firms, with 234 companies being surveyed [1] - Fund companies conducted research on 191 companies, while private equity firms investigated 82 companies [1] - Ganfeng Lithium received the highest attention with 91 institutions participating in its research, followed by Hanhai Group also with 91 institutions [1][2] Group 2: Fund Flow and Stock Performance - Among the stocks investigated by more than 20 institutions, 11 experienced net inflows in the past five days, with Guorui Technology seeing the highest net inflow of 284 million yuan [1] - Hanhai Group and Lais Information also had significant net inflows of 79 million yuan and 70 million yuan respectively [1] - In terms of stock performance, 31 stocks increased in value, with Demingli, Shuanghuan Transmission, and Guangdong Hongda leading with gains of 31.55%, 24.06%, and 21.07% respectively [2] Group 3: Detailed Company Insights - Ganfeng Lithium (603087) was investigated once by 91 institutions, with a closing price of 73.60 yuan and a slight decline of 0.35% [2] - Hanhai Group (001221) also had 91 institutions participating, closing at 67.41 yuan with a notable increase of 17.64% [2] - Dingtong Technology (688668) was investigated by 77 institutions, closing at 108.94 yuan with a gain of 3.26% [2]

Core Insights - The Medical Health R Index (480016) closed at 8194.9 points on September 22, with a slight increase of 0.05% and a trading volume of 32.204 billion yuan, indicating a turnover rate of 1.01% [1] Index Performance - Among the index constituents, 18 stocks rose while 32 stocks fell, with Ganli Pharmaceutical leading the gainers at a 3.76% increase, and Prologis Pharmaceutical leading the decliners with a 3.21% decrease [1] Top Constituents - The top ten constituents of the Medical Health R Index are as follows: - WuXi AppTec (sh603259) holds a weight of 13.58% and closed at 109.03 yuan, with a 0.26% increase [1] - Heng Rui Medicine (sh600276) has a weight of 10.87% and closed at 71.05 yuan, with a 2.01% increase [1] - Mindray Medical (sz300760) has a weight of 8.17% and closed at 237.15 yuan, with a 0.91% increase [1] - United Imaging Healthcare (sh688271) has a weight of 4.14% and closed at 145.93 yuan, with a 1.33% decrease [1] - Pianzai Shou (sh600436) has a weight of 3.91% and closed at 197.80 yuan, with a 0.72% decrease [1] - Aier Eye Hospital (sz300015) has a weight of 3.58% and closed at 12.37 yuan, with a 0.88% decrease [1] - Kelun Pharmaceutical (sz002422) has a weight of 2.59% and closed at 37.29 yuan, with a 2.39% increase [1] - Xinhecheng (sz002001) has a weight of 2.37% and closed at 23.73 yuan, with a 2.23% decrease [1] - Fosun Pharma (sh600196) has a weight of 2.26% and closed at 30.79 yuan, with a 0.45% decrease [1] - Tenzhuaosi (sz002252) has a weight of 2.07% and closed at 6.75 yuan, with a 0.30% decrease [1] Capital Flow - The Medical Health R Index constituents experienced a net outflow of 559 million yuan from institutional investors, while retail investors saw a net inflow of 583 million yuan [1] - Detailed capital flow for key stocks includes: - WuXi AppTec saw a net inflow of 27.8 million yuan from institutional investors [2] - Mindray Medical had a net inflow of 7.942 million yuan from institutional investors [2] - Heng Rui Medicine experienced a net outflow of 64.014 million yuan from institutional investors [2] - Ganli Pharmaceutical had a net inflow of 58.156 million yuan from institutional investors [2] - Kelun Pharmaceutical saw a net inflow of 42.940 million yuan from institutional investors [2]

Core Viewpoint - The demand for insulin in China is rapidly increasing due to the large diabetic patient population, with Aspart insulin being a key product that effectively controls postprandial hyperglycemia and is now more accessible due to its inclusion in the medical insurance catalog [1][7]. Market Overview - Aspart insulin is a commonly used rapid-acting insulin analog, primarily for controlling blood sugar in type 1 and type 2 diabetes patients, with effects starting within 10-20 minutes and lasting about 4-6 hours [2][3]. - The market size for Aspart insulin in China is projected to reach 8.451 billion yuan in 2024, representing a year-on-year growth of 5.33% and accounting for 31.1% of the overall insulin market [1][7]. Market Policies - The Chinese government has implemented various policies to regulate the insulin industry, ensuring quality and safety while promoting healthy and high-quality development [3]. Industry Chain - The upstream of the Aspart insulin industry includes animal-derived insulin raw materials, intermediates, active pharmaceutical ingredients, packaging materials, and pharmaceutical equipment. The midstream consists of Aspart insulin production companies, while the downstream includes medical institutions, pharmacies, e-commerce channels, and end consumers [4][5]. Patient Demographics - The prevalence of diabetes in China is on the rise, with an estimated 148 million diabetic patients by 2024, marking a year-on-year increase of 4.89%, which drives the demand for Aspart insulin [6]. Competitive Landscape - The centralized procurement policy has reshaped the competitive landscape of the insulin market, leading to price reductions but also providing more market opportunities for selected companies. As of April 2024, six companies were selected for Aspart insulin in the national procurement process, indicating a trend towards increased market share for domestic products [8][9]. Company Profiles - **Ganli Pharmaceutical**: Engaged in the research, production, and sales of insulin analogs, with a projected revenue of 3.045 billion yuan and a gross profit of 2.279 billion yuan in 2024, achieving a gross margin of 74.83% [10]. - **Tonghua Dongbao Pharmaceutical**: Focused on drug research and production, with a projected revenue of 2.01 billion yuan and a gross profit of 1.485 billion yuan in 2024, achieving a gross margin of 73.90% [11]. Future Development Trends - The inclusion of Aspart insulin in the medical insurance catalog will continue to impact its market sales, with ongoing adjustments in reimbursement policies and centralized procurement driving companies to optimize pricing strategies and enhance product accessibility in grassroots medical markets [12].

Market Overview - The Shanghai Composite Index rose by 0.37% on September 17, with 20 industries experiencing gains, led by the power equipment and automotive sectors, which increased by 2.55% and 2.05% respectively [1] - Conversely, the agriculture, forestry, animal husbandry, and fishery sectors, along with retail, saw declines of 1.02% and 0.98% respectively [1] - The pharmaceutical and biotechnology sector fell by 0.23% [1] Capital Flow Analysis - The main capital outflow from the two markets totaled 38.306 billion yuan, with five industries seeing net inflows [1] - The power equipment sector led the net inflow with 1.835 billion yuan, followed by the automotive sector with 1.142 billion yuan [1] - The non-bank financial sector experienced the largest net outflow, totaling 5.229 billion yuan, followed by the computer sector with a net outflow of 4.455 billion yuan [1] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector saw a net outflow of 3.977 billion yuan, with 474 stocks in the sector; 135 stocks rose while 327 fell [2] - The top net inflow stocks included WuXi AppTec with 352 million yuan, followed by Hengrui Medicine and Boteng Co., with inflows of 312 million yuan and 55.426 million yuan respectively [2] - Nine stocks in the sector experienced net outflows exceeding 100 million yuan, with the largest outflows from Guangsheng Tang, Sino Medical, and Ganli Pharmaceutical, amounting to 253 million yuan, 164 million yuan, and 140 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - WuXi AppTec: +2.09%, turnover rate 2.01%, net inflow 351.585 million yuan [2] - Hengrui Medicine: +1.42%, turnover rate 0.92%, net inflow 312.024 million yuan [2] - Boteng Co.: -0.93%, turnover rate 6.09%, net inflow 55.426 million yuan [2] Top Losers in Pharmaceutical Sector - Guangsheng Tang: -4.40%, turnover rate 9.74%, net outflow -252.737 million yuan [3] - Sino Medical: -1.74%, turnover rate 5.85%, net outflow -164.152 million yuan [3] - Ganli Pharmaceutical: -1.74%, turnover rate 2.88%, net outflow -139.861 million yuan [3]

Overview - The demand for insulin in China is rapidly increasing due to a large diabetic patient population, with the market for insulin glargine projected to reach 6.083 billion yuan in 2024, representing a year-on-year growth of 4.13% and accounting for 22.36% of the overall insulin market [1][9]. Market Policy - The Chinese government has implemented a series of policies to regulate the production, sales, and use of insulin, including insulin glargine, to ensure drug quality and safety, promoting healthy and high-quality industry development [4][5]. Industry Chain - The upstream of the insulin glargine industry includes suppliers of raw materials such as gene-engineered strains, culture media, and packaging materials, while the midstream consists of production companies, and the downstream includes medical institutions and pharmacies [6][7]. Current Development - The prevalence of diabetes in China is on the rise, with an estimated 148 million diabetic patients in 2024, marking a year-on-year increase of 4.89%, which drives the demand for insulin glargine [8][9]. Competitive Landscape - The market is transitioning from foreign dominance to the rise of domestic companies, with a multi-faceted competitive landscape involving original research companies, leading domestic firms, and follow-up entrants. Domestic companies like Ganli Pharmaceutical and Tonghua Dongbao have gained market share through centralized procurement policies [10][11]. Company Profiles - **Ganli Pharmaceutical**: Focuses on the research, production, and sales of insulin analogs, with projected revenue of 3.045 billion yuan and a gross profit of 2.279 billion yuan in 2024, achieving a gross margin of 74.83% [11][12]. - **Tonghua Dongbao**: Engaged in drug research and production, with a focus on diabetes and endocrine treatments, reporting a revenue of 2.01 billion yuan and a gross profit of 1.485 billion yuan in 2024, with a gross margin of 73.90% [12]. Future Trends - Domestic companies are expected to continue improving product quality and reducing the gap with imported products, leading to an increase in market share for domestic insulin glargine as centralized procurement policies advance, and more products may enter the international market [10][12].